This site and its domain are for sale. Email the owner if you want to talk about it.

compoundglp.com

The Compounding Pharmacy Quality Scorecard

Twenty questions that separate a careful compounder from a risky one, drawn from FDA inspection findings, USP standards and independent potency testing, with what a good answer sounds like.

The Compounding Pharmacy Quality Scorecard is twenty questions you could put to a compounding pharmacy, with what a reassuring answer and a worrying answer sound like. The premise is that a careful compounder enjoys these questions. It has the paperwork, it knows which section of federal law it lives under, and it can tell you which form of the molecule is in the vial. A risky one tends to treat the questions as rude, or answers a different and easier question.

Read each row left to right. The first column is the question. The second is what a pharmacy with its house in order tends to say. The third is the answer that should make you sit up a little. The last column is the regulatory basis, so you can see where the expectation comes from. Some rows are hard law, such as the salt form rules. Others are softer signals, such as whether a pharmacy will discuss its inspection history, where the law does not require it to share anything with you.

Some things are still open. The promised independent potency testing is the weakest leg of this stool: no independent potency or sterility test results are in the record behind this scorecard, so those cells say not settled. The FDA’s May 2026 proposal to close the last large-scale 503B pathway for semaglutide, tirzepatide and liraglutide has not been finalized. The litigation over the shortage deadlines has its own timetable. The rows on legal footing describe the rules as they stand, not as they may end up.

Who regulates the pharmacy

Question to askWhat a good answer sounds likeWhat a worrying answer sounds likeBasis
Are you a 503A pharmacy or a 503B outsourcing facility?A clear answer either way. A 503B outsourcing facility is registered with the FDA and must follow full CGMP under 21 CFR Parts 210 and 211. A 503A pharmacy answers mainly to its state board, is not required to register with the FDA and is exempt from those CGMP rules for patient-specific prescriptions.Uncertainty, or a claim to be FDA approved. Compounded drugs are not FDA-approved products.Federal law on 503A and 503B; FD&C Act section 501(a)(2)(B)
If 503A, is every preparation made against a patient-specific prescription?Yes, each one is tied to an individual prescription.Stock made in advance and allocated to prescriptions later. Large batches without patient-specific prescriptions are a 503B activity.Section 503A; Section 503B
Who does the compounding?A licensed pharmacist in a state-licensed pharmacy or a Federal facility, or a licensed physician.Vague references to a partner, a lab or a supplier.21 U.S.C. 353a
Do you hold PCAB accreditation?Yes, with the accreditation verifiable. Washington and Ohio now require verifiable PCAB accreditation for nonresident compounding pharmacy licensure.No, followed by a claim that it means nothing. It is optional, but it is third-party review.Pharmacy Compounding Accreditation Board; Washington and Ohio licensure rules

The active ingredient

Question to askWhat a good answer sounds likeWhat a worrying answer sounds likeBasis
Which form of the molecule do you use?The base form of semaglutide, the form used in FDA-approved products.Semaglutide sodium or semaglutide acetate. The FDA treats these as different active ingredients and told the National Association of Boards of Pharmacy on April 27, 2023 that it knew of no basis for compounding with them.FDA notice to NABP; FDA statements on salt forms
Which legal pathway does your bulk ingredient meet?Under 503A there are exactly three: an applicable USP or NF monograph, being a component of an FDA-approved drug, or appearing on an FDA-developed list. Semaglutide has no monograph. The base form meets the second pathway.An answer that skips the pathways. Semaglutide sodium and acetate meet none of the three.21 U.S.C. 353a(b)(1)(A)
Where does the bulk ingredient come from?A registered manufacturer, with a valid certificate of analysis for the bulk ingredient.From Novo Nordisk. Novo Nordisk does not sell semaglutide base or any form of the active ingredient to compounding pharmacies.Section 503A bulk substance rules
What does the label call the active ingredient?The exact form used, so the label matches the vial.Simply semaglutide, on a salt-form product. That exposes the pharmacy to misbranding findings, state board complaints and civil liability from patients not told they received a substitute.Analysis of salt-form labeling
Do your other ingredients meet USP standards?Non-bulk ingredients meet any applicable USP or NF monograph and the USP chapter on pharmacy compounding.No idea what monograph means.21 U.S.C. 353a(b)(1)(B)

Sterility, testing and process

Question to askWhat a good answer sounds likeWhat a worrying answer sounds likeBasis
Which USP chapters do you work to?A 503A pharmacy names USP 795 and USP 797 plus state board rules. A 503B facility names CGMP, and USP 797 and 800 sterile standards keep applying during a wind-down after delisting.No chapter named. Non-sterile compounding environments were among the early safety signals with compounded semaglutide.USP 795, 797 and 800; state board rules
How do you set the beyond-use date?For a 503B facility, formulation-specific stability data, which FDA draft CGMP guidance expects.A default date with no stability work behind it at an outsourcing facility. A 503A pharmacy may rely on USP 797 default categories.FDA draft CGMP guidance for outsourcing facilities
Does an outside lab test every batch?Potency, sterility and endotoxin results, shown without being chased. Which batch tests federal law requires of each type of compounder: not settled.Testing described in general terms with no results to show.Independent potency testing results: not public
Do you validate your processes?For a 503B facility, yes, every process, under CGMP.Validation described as something only drug manufacturers do.CGMP requirements for 503B
What did your last FDA inspection find?The observations and the responses, discussed plainly. Production and process control deficiencies made up close to 29 percent of all Form 483 observations issued to outsourcing facilities, in a review presented at the FDA Compounding Quality Center of Excellence 2024 conference.We have never had any findings, from a facility that cannot say when it was last inspected.FDA Form 483 data
How do you run smoke studies and media fills?Smoke studies done properly and media fill records kept as originally recorded.Records that get tidied up. On September 18, 2026 an FDA warning letter to a Houston compounding pharmacy cited inadequate smoke studies and rewritten media fill records.FDA warning letter, September 18, 2026
Question to askWhat a good answer sounds likeWhat a worrying answer sounds likeBasis
What lets you compound this drug now?A basis that does not rely on the shortage list. Copies of approved drugs are allowed only while the product is on that list. The FDA ended the semaglutide shortage on February 21, 2025, with wind-downs to April 22, 2025 for 503A and May 22, 2025 for 503B. The 503B tirzepatide grace period ended March 19, 2025.It is on the shortage list. On March 10, 2025 the FDA said 503A and 503B compounders must cease compounding semaglutide injection products or risk enforcement.FDA declaratory order and guidance
How do you document that a preparation differs significantly for a patient?A real clinical reason recorded for that patient.Boilerplate. The September 18, 2026 warning letter cited pretextual significant-difference determinations and boilerplate prescribing records.FDA warning letter, September 18, 2026
How do pending lawsuits and rules affect you?A precise account. Industry groups secured injunctions that temporarily prevented a complete shutdown, the deadlines were tied to court rulings on the OFA motion, and a May 2026 FDA proposal would, if finalized, close the last large-scale 503B pathway.The lawsuits mean anything goes. Final outcome: not settled.OFA v. FDA; FDA May 2026 proposal

Dispensing and marketing

Question to askWhat a good answer sounds likeWhat a worrying answer sounds likeBasis
What counseling comes with the vial?Pharmacist counseling on how the drug is administered.A vial and syringes in a box. In a 2023 poison control case series, one patient received exactly that with no pharmacist counseling.Case series of administration errors
Which pharmacy actually compounds the product sold under your brand?The compounding pharmacy is named, and the product is not described as the same as the approved drug.A telehealth brand name only, or same as the brand language. FDA warning letters name the telehealth platform itself as responsible for misbranding.FDA warning letters to telehealth companies

How to read this

No single row clears or condemns a pharmacy. The salt form, bulk pathway and post-shortage rows rest on statute and FDA statements, so a bad answer there is a legal problem as well as a quality one. The testing, inspection and counseling rows are signals. They describe habits that show up in FDA findings, not boxes the law makes a pharmacy show you. The 503A and 503B distinction runs through everything: the same question has a different right answer depending on which rulebook applies, which is why the first row comes first.

What would change it

The FDA’s May 2026 proposal on 503B compounding of semaglutide, tirzepatide and liraglutide, if finalized, would rewrite the legal footing rows. Rulings in the OFA litigation could move the deadlines again. Published independent potency, sterility and endotoxin testing would let the testing row say something firmer than not settled. A USP monograph for semaglutide would change the bulk pathway row, since its absence is why base form status matters so much now.

Sources

  1. Compounded Semaglutide vs Brand Name Comparison: What's Actually in Your Injection?
  2. Semaglutide Salt Forms: Why the Base Matters
  3. 503A vs. 503B: A Quick-Guide to Compounding Pharmacy Designations & Regulations
  4. DEA Registration Requirements for Compounding Pharmacies
  5. cGMP Expectations for Outsourcing Facilities
  6. 21 U.S. Code § 353a - Pharmacy compounding | U.S. Code | US Law | LII / Legal Information Institute
  7. Semaglutide Sodium vs Base: What FDA Says and What to Ask
  8. The FDA Removes Semaglutide from the Drug Shortage List
  9. Semaglutide Compounding Pharmacy: What's Legal In 2026
  10. FDA Warning Letters to Telehealth Companies Selling Compounded Drugs
  11. FDA's Semaglutide Shortage Resolution: Legal Implications And Risks For Compounding Pharmacies | Legal 500
  12. Compounded GLP-1 Marketing After the Shortage Ended
  13. Is your compounded semaglutide and tirzepatide safe?
  14. Compounding After a Drug Leaves the Shortage List
  15. FDA clarifies position on compounding semaglutide sodium
  16. The Shot Heard ‘Round the Pharmacy’: FDA Takes Aim at GLP-1 Compounders | ArentFox Schiff
  17. Compounded Tirzepatide: Meaning, Risks, Regulator Warnings
  18. Alert to All Compounders: Update in FDA Tirzepatide Litigation - Frier Levitt
  19. Administration errors of compounded semaglutide reported to a poison control center-Case series
  20. Quality Control In Compounding Pharmacy: 2026 Checklist

Compound GLP explains the law and published research. It is not medical or legal advice, and it never recommends a dose, a pharmacy or a product. Talk to a clinician before you start, stop or change any medicine.